ApoE Lipidation State Directs Immunometabolic Reprogramming of Human Microglia
Shiferaw, T. G.; Sarkar, S.; Baker, K. M.; Wooldridge, R. S.; Binfet, H. M.; Prozapas, V. N.; Ogbu, C. P.; Schepmoes, A. A.; Attah, I. K.; Niemeyer, C. S.; Sprenger, K. G.; Eckel, R. H.; Hassell, J. E.; Melchior, J. T.; Bruce, K. D.
Show abstract
IntroductionApoE4 is the strongest genetic risk factor for Alzheimers disease (AD). Emerging evidence suggests that ApoE4 increases AD risk by disrupting microglial metabolism and function. However, whether ApoE lipidation state contributes to microglial dysfunction remains poorly understood. MethodsHuman microglia were treated with lipid-free or lipid-bound ApoE3 or ApoE4. Label-free live-cell holotomography and global proteomics were used to assess isoform- and lipidation-specific effects on lipid droplet dynamics, mitochondrial morphology, and microglial phenotype. ResultsApoE4 treatment resulted in fewer but enlarged lipid droplets and increased mitochondrial fragmentation compared to ApoE3, effects that were enhanced by lipid-bound ApoE4. Proteomic analyses revealed a strong type I interferon response in cells exposed to lipid-free ApoE, which was exacerbated by lipid-free ApoE4. DiscussionThese findings indicate that lipid-bound ApoE4 drives metabolic reprogramming, whereas lipid-free ApoE4 promotes inflammatory signaling, identifying ApoE lipidation as a critical modifier of ApoE4-associated AD risk.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.